TSEAC to discuss BSE
This article was originally published in The Tan Sheet
Executive Summary
FDA Transmissible Spongiform Encephalopathies Advisory Committee will meet July 17-18 to consider whether results of five gelatin studies conducted with European Commission funding demonstrate a reduction in infectivity from BSE sufficient to protect human health. Committee will discuss safety of bovine bone gelatin in oral and topical drugs, cosmetics and recommend changes to FDA position if necessary. All five studies, released July 11 on 1FDA's Web site, tested "gelatin manufacturing processes...using artificially high infective raw material [and] resulted in a final gelatin which, after purification, has not induced TBSE disease after intracerebral injection in animals of the same species." TSEAC meeting will take place at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...